NuCana (NCNA) Receivables (2016 - 2025)
NuCana's (NCNA) quarterly Receivables came in at $1.1 million in Q4 2025, down 6.4% year-on-year from $1.2 million in Q4 2024, and down 71.88% quarter-over-quarter from $4.0 million in Q3 2025.
NuCana (NCNA) Receivables (2016 - 2025) Analysis & Trends
NuCana has disclosed Receivables across 10 years of filings, most recently posting $1.1 million for Q4 2025.
- Receivables for Q4 2025 came in at $1.1 million, down 6.4% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.1 million (down 6.4% YoY), and the FY2025 annual result was $1.1 million, down 6.84% from the prior year.
- Receivables came in at $1.1 million for Q4 2025 at NuCana, down from $4.0 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $8.3 million in Q3 2022 to a low of $1.1 million in Q4 2025.
- The 5-year median for Receivables is $4.2 million (2023), against an average of $4.1 million.
- Across the five-year window, Receivables plunged 65.72% in 2024 and soared 170.87% in 2025, its largest moves.
- NuCana's Receivables stood at $5.6 million in 2021, then slipped by 17.14% to $4.7 million in 2022, then retreated by 28.35% to $3.3 million in 2023, then sank by 63.85% to $1.2 million in 2024, then dropped by 6.4% to $1.1 million in 2025.
- The last three Receivables figures came in at $1.1 million (Q4 2025), $4.0 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 4.02 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 3.51 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 3.27 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 4.66 Mn |
| Sep 30, 2022 | 8.31 Mn |
| Jun 30, 2022 | 4.95 Mn |
| Mar 31, 2022 | 5.09 Mn |
| Dec 31, 2021 | 5.62 Mn |
| Sep 30, 2021 | 7.08 Mn |
| Jun 30, 2021 | 5.87 Mn |
| Mar 31, 2021 | 6.64 Mn |